[Velcade in multiple myeloma]

Area of Science:

• Oncology
• Hematology
• Pharmacology

Background:

• Multiple myeloma (MM) is a progressive plasma cell malignancy.
• Refractory or progressive MM poses significant treatment challenges.
• Novel therapeutic agents are crucial for improving patient outcomes.

Purpose of the Study:

• To evaluate the efficacy of Velcade (bortezomib) therapy.
• To assess Velcade's role in managing progressive or refractory multiple myeloma.
• To determine response rates and safety in a cohort of MM patients.

Main Methods:

• A cohort of 18 patients with progressive or refractory MM received Velcade intravenously.
• Treatment involved multiple cycles administered over a defined period.
• Efficacy was assessed using European Group for Blood and Marrow Transplantation (EBMT) criteria.

Main Results:

• Overall efficacy was observed in 68% of patients (16 out of 16 assessed).
• Responses included partial remission (PR) in 9 patients and complete remission (CR) in 1 patient.
• Velcade was used as induction therapy before high-dose chemotherapy and autotransplantation in some patients, with favorable outcomes.

Conclusions:

• Velcade is an effective antitumor drug for progressive and refractory multiple myeloma.
• It can be utilized as a monotherapy or in combination regimens.
• The drug demonstrates potential in inducing remission and facilitating subsequent treatment.